GLPwatch
Xultophy for Gastroparesis
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCXultophy (liraglutide) is not FDA-approved for gastroparesis, and any use for this condition is off-label or investigational. Research suggests liraglutide has a short-lived effect on gastric emptying but long-lasting effects on body weight, with some studies exploring its impact on gastric function or related symptoms.
AI summary of the sources below.
| Drug | Xultophy (liraglutide) |
|---|---|
| Condition | Gastroparesis |
| Approval status | Investigational / off-label |
| Research papers | 9 |
Xultophy is not FDA-approved for gastroparesis; the research below reflects investigational or off-label study only.
Research on liraglutide for gastroparesis (9)
- Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight.
- Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
- Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
- Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
- Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.
- Intelligent Escape System for the Oral Delivery of Liraglutide: A Perfect Match for Gastrointestinal Barriers.
- Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide.
- Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery.
- The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats.